Odanacatib Restores Trabecular Bone of Skeletally Mature Female Rabbits With Osteopenia but Induces Brittleness of Cortical Bone: A Comparative Study of the Investigational Drug With PTH, Estrogen, and Alendronate

被引:10
作者
Khan, Mohd Parvez [1 ,2 ]
Singh, Atul Kumar [3 ]
Singh, Abhishek Kumar [4 ]
Shrivastava, Pragya [3 ]
Tiwari, Mahesh Chandra [1 ,2 ]
Nagar, Geet Kumar [1 ,2 ]
Bora, Himangshu Kousik [5 ]
Parameswaran, Venkitanarayanan [6 ]
Sanyal, Sabyasachi [4 ]
Bellare, Jayesh R. [3 ,7 ]
Chattopadhyay, Naibedya [1 ,2 ]
机构
[1] CSIR, Cent Drug Res Inst, Div Endocrinol, 10 Janakipuram Extn,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India
[2] CSIR, Cent Drug Res Inst, Ctr Res Anabol Skeletal Targets Hlth & Illness AS, 10 Janakipuram Extn,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India
[3] Indian Inst Technol, Ctr Res Nanotechnol & Sci, Bombay 400076, Maharashtra, India
[4] CSIR, Cent Drug Res Inst, Div Biochem, Lucknow, Uttar Pradesh, India
[5] CSIR, Cent Drug Res Inst, Dept Lab Anim, Lucknow, Uttar Pradesh, India
[6] Indian Inst Technol, Dept Mech Engn, Kanpur 208016, Uttar Pradesh, India
[7] Indian Inst Technol, Dept Chem Engn, Bombay 400076, Maharashtra, India
关键词
CATHEPSIN K; ODANACATIB; TISSUE MINERALIZATION; CRYSTALLINITY; STROMAL CELLS; CATHEPSIN-K INHIBITORS; MICRO-COMPUTED TOMOGRAPHY; MINERAL DENSITY; POSTMENOPAUSAL WOMEN; PARATHYROID-HORMONE; OSTEOCLAST FORMATION; CANCER-CELLS; IN-VITRO; OSTEOPOROSIS; RESORPTION;
D O I
10.1002/jbmr.2719
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cathepsin K (CK), a lysosomal cysteine protease, is highly expressed in mature osteoclasts and degrades type 1 collagen. Odanacatib (ODN) is a selective and reversible CK inhibitor that inhibits bone loss in preclinical and clinical studies. Although an antiresorptive, ODN does not suppress bone formation, which led us to hypothesize that ODN may display restorative effect on the osteopenic bones. In a curative study, skeletally mature New Zealand rabbits were ovarectomized (OVX) and after induction of bone loss were given a steady-state exposure of ODN (9 mM/d) for 14 weeks. Sham-operated and OVX rabbits treated with alendronate (ALD), 17b-estradiol (E2), or parathyroid hormone (PTH) served as various controls. Efficacy was evaluated by assessing bone mineral density (BMD), bone microarchitecture (using micro-computed tomography), fluorescent labeling of bone, and biomechanical strength. Skeletal Ca/P ratio was measured by scanning electron microscopy (SEM) with X-ray microanalysis, crystallinity by X-ray diffraction, and bone mineral density distribution (tissue mineralization) by backscattered SEM. Between the sham and ODN-treated osteopenic groups, lumbar and femur metaphyseal BMD, Ca/P ratio, trabecular microstructure and geometric indices, vertebral compressive strength, trabecular lining cells, cortical parameters (femoral area and thickness and periosteal deposition), and serum P1NP were largely comparable. Skeletal improvements in ALD-treated or E2-treated groups fell significantly short of the sham/ODN/PTH group. However, the ODN group displayed reduced ductility and enhanced brittleness of central femur, which might have been contributed by higher crytallinity and tissue mineralization. Rabbit bone marrow stromal cells expressed CK and when treated with ODN displayed increased formation of mineralized nodules and decreased apoptosis in serum-deficient medium compared with control. In vivo, ODN did not suppress remodeling but inhibited osteoclast activity more than ALD. Taken together, we show that ODN reverses BMD, skeletal architecture, and compressive strength in osteopenic rabbits; however, it increases crystallinity and tissue mineralization, thus leading to increased cortical bone brittleness. (c) 2015 American Society for Bone and Mineral Research.
引用
收藏
页码:615 / 629
页数:15
相关论文
共 58 条
  • [11] Standardized Nomenclature, Symbols, and Units for Bone Histomorphometry: A 2012 Update of the Report of the ASBMR Histomorphometry Nomenclature Committee
    Dempster, David W.
    Compston, Juliet E.
    Drezner, Marc K.
    Glorieux, Francis H.
    Kanis, John A.
    Malluche, Hartmut
    Meunier, Pierre J.
    Ott, Susan M.
    Recker, Robert R.
    Parfitt, A. Michael
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28 (01) : 1 - 16
  • [12] EVIDENCE THAT INTERMITTENT TREATMENT WITH PARATHYROID-HORMONE INCREASES BONE-FORMATION IN ADULT-RATS BY ACTIVATION OF BONE LINING CELLS
    DOBNIG, H
    TURNER, RT
    [J]. ENDOCRINOLOGY, 1995, 136 (08) : 3632 - 3638
  • [13] Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts
    Drake, FH
    Dodds, RA
    James, IE
    Connor, JR
    Debouck, C
    Richardson, S
    LeeRykaczewski, E
    Coleman, L
    Rieman, D
    Barthlow, R
    Hastings, G
    Gowen, M
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (21) : 12511 - 12516
  • [14] MAFFUCCIS SYNDROME - CASE REPORT WITH A NORMAL KARYOTYPE
    ELMORE, SM
    CANTRELL, WC
    [J]. JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1966, A 48 (08) : 1607 - &
  • [15] Mineral maturity and crystallinity index are distinct characteristics of bone mineral
    Farlay, Delphine
    Panczer, Gerard
    Rey, Christian
    Delmas, Pierre D.
    Boivin, Georges
    [J]. JOURNAL OF BONE AND MINERAL METABOLISM, 2010, 28 (04) : 433 - 445
  • [16] Alendronate mechanism of action:: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
    Fisher, JE
    Rogers, MJ
    Halasy, JM
    Luckman, SP
    Hughes, DE
    Masarachia, PJ
    Wesolowski, G
    Russell, RGG
    Rodan, GA
    Reszka, AA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (01) : 133 - 138
  • [17] In vivo measurement of radius calcium phosphorus ratio by X-ray absorptiometry
    Fountos, G
    Tzaphlidou, M
    Kounadi, E
    Glaros, D
    [J]. APPLIED RADIATION AND ISOTOPES, 1999, 51 (03) : 273 - 278
  • [18] Raman spectroscopic detection of changes in bioapatite in mouse femora as a function of age and in vitro fluoride treatment
    Freeman, JJ
    Wopenka, B
    Silva, MJ
    Pasteris, JD
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2001, 68 (03) : 156 - 162
  • [19] The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K
    Gauthier, Jacques Yves
    Chauret, Nathalie
    Cromlish, Wanda
    Desmarais, Sylvie
    Duong, Le T.
    Falgueyret, Jean-Pierre
    Kimmel, Donald B.
    Lamontagne, Sonia
    Leger, Serge
    LeRiche, Tammy
    Li, Chun Sing
    Masse, Frederic
    Mckay, Daniel J.
    Nicoll-Griffith, Deborah A.
    Oballa, Renata A.
    Palmer, James T.
    Percival, M. David
    Riendeau, Denis
    Robichaud, Joel
    Rodan, Gideon A.
    Rodan, Sevgi B.
    Seto, Carmai
    Therien, Michel
    Truong, Vouy-Linh
    Venuti, Michael C.
    Wesolowski, Gregg
    Young, Robert N.
    Zamboni, Robert
    Black, W. Cameron
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (03) : 923 - 928
  • [20] Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency
    Gelb, BD
    Shi, GP
    Chapman, HA
    Desnick, RJ
    [J]. SCIENCE, 1996, 273 (5279) : 1236 - 1238